The company has developed a novel antibody platform to address significant needs in infectious diseases, including pneumococcal pneumonia which results in the hospitalization of more than 1 million people annually in the U.S. and Europe. Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org i2E, Inc., and AcceleVenture Partners recently closed aRead more